PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
BUSINESS
EU Approves Padcev-Keytruda for Earlier Bladder Cancer Use
European regulatory authorities have approved Astellas Pharma’s antibody drug conjugate Padcev (enfortumab vedotin) in combination with Merck’s PD-1 inhibitor Keytruda (pembrolizumab) for earlier use in bladder cancer. Astellas said on June 24 that the European Commission gave the green light…
To read the full story
Related Article
- EU Expands Padcev-Keytruda Use in Resectable MIBC
October 26, 2026
- Padcev-Keytruda Gets CHMP Nod for Expanded MIBC Use
September 18, 2026
- Padcev-Keytruda Gets CHMP Nod for Cisplatin-Ineligible Bladder Cancer
May 25, 2026
- EMA Starts Review of Padcev-Keytruda for Perioperative Bladder Cancer
December 2, 2025
BUSINESS
- Japan Pharma Earnings Season Opens as Drug Price Cuts, Patent Cliffs Test Growth
October 27, 2026
- Otsuka Ramps Up CVC Investments, Already Backs 2 Biotechs
October 27, 2026
- Medipal Shareholder Silchester Seeks Court Nod for Extraordinary Meeting
October 27, 2026
- NEC Joins European AI Vaccine Project for Pandemic Preparedness
October 27, 2026
- Mochida Kicks Off Japan PIII of Morning Sickness Drug
October 27, 2026
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…